Related references
Note: Only part of the references are listed.Temperature and pH-Dependent Stability of Mitragyna Alkaloids
Stephanie Basiliere et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2020)
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected lndole-Based Kratom Alkaloids
Samuel Obeng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids
Shyam H. Kamble et al.
TOXICOLOGY LETTERS (2020)
Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects
Matthew G. McDonald et al.
DRUG METABOLISM AND DISPOSITION (2020)
The Chemistry of Kratom [Mitragyna speciosa]: Updated Characterization Data and Methods to Elucidate Indole and Oxindole Alkaloids
Laura Flores-Bocanegra et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions
D. A. Todd et al.
SCIENTIFIC REPORTS (2020)
The internet market for Kratom, an opioid alternative and variably legal recreational drug
Rebecca S. Williams et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2020)
Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model
Yannick Parmentier et al.
XENOBIOTICA (2019)
Kratom exposures reported to United States poison control centers: 2011-2017
Sara Post et al.
CLINICAL TOXICOLOGY (2019)
Metabolism of Butyrylfentanyl in Fresh Human Hepatocytes: Chemical Synthesis of Authentic Metabolite Standards for Definitive Identification
Tatsuyuki Kanamori et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2019)
Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
Anitha Saravanakumar et al.
CLINICAL PHARMACOKINETICS (2019)
Unintentional Drug Overdose Deaths with Kratom Detected-27 States, July 2016-December 2017
Emily O'Malley Olsen et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates
Diane Ramsden et al.
DRUG METABOLISM AND DISPOSITION (2019)
Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction
Rhome L. Hughes
FORENSIC SCIENCE MEDICINE AND PATHOLOGY (2019)
Deaths in Colorado Attributed to Kratom
Ken Gershman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)
Shyam H. Kamble et al.
XENOBIOTICA (2019)
Current perspectives on the impact of Kratom use
Charles Veltri et al.
SUBSTANCE ABUSE AND REHABILITATION (2019)
The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research
Jack E. Henningfield et al.
PSYCHOPHARMACOLOGY (2018)
Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation
Dan-Dan Tian et al.
DRUG METABOLISM AND DISPOSITION (2018)
Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary
Mary F. Paine et al.
DRUG METABOLISM AND DISPOSITION (2018)
Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach
Emily J. Johnson et al.
DRUG METABOLISM AND DISPOSITION (2018)
Improved Predictions of Drug–Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A
Jaydeep Yadav et al.
MOLECULAR PHARMACEUTICS (2018)
The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse
Andrew C. Kruegel et al.
NEUROPHARMACOLOGY (2018)
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance
Douglas C. Throckmorton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of CYP Inducers/Inhibitors on Topiramate Concentration: Clinical Value of Therapeutic Drug Monitoring
Yoshiaki Yamamoto et al.
THERAPEUTIC DRUG MONITORING (2017)
Physicochemical Characterization of Mitragyna speciosa Alkaloid Extract and Mitragynine using In Vitro High Throughput Assays
Wai Mun Kong et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2017)
Trends in Tramadol: Pharmacology, Metabolism, and Misuse
Karen Miotto et al.
ANESTHESIA AND ANALGESIA (2017)
4-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients
Caroline Gjestad et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype
Katalin Toth et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
Andrew C. Kruegel et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates
Yoko Mano et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Following the Roots of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries
Eduardo Cinosi et al.
BIOMED RESEARCH INTERNATIONAL (2015)
P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms
Matthew G. McDonald et al.
DRUG METABOLISM AND DISPOSITION (2015)
Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction
Brandon T. Gufford et al.
DRUG METABOLISM AND DISPOSITION (2015)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
K. R. Crews et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway
Austin C. Li et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2014)
Identification of Diet-Derived Constituents as Potent Inhibitors of Intestinal Glucuronidation
Brandon T. Gufford et al.
DRUG METABOLISM AND DISPOSITION (2014)
Metabolic Activation of the Indoloquinazoline Alkaloids Evodiamine and Rutaecarpine by Human Liver Microsomes: Dehydrogenation and Inactivation of Cytochrome P450 3A4
Bo Wen et al.
DRUG METABOLISM AND DISPOSITION (2014)
Assessment of a Candidate Marker Constituent Predictive of a Dietary Substance-Drug Interaction: Case Study with Grapefruit Juice and CYP3A4 Drug Substrates
Garrett R. Ainslie et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction
Zurina Hassan et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2013)
Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities
N. A. Hanapi et al.
PHARMACOGNOSY RESEARCH (2013)
Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma
Jialin Mao et al.
DRUG METABOLISM AND DISPOSITION (2011)
An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
Andrew Parkinson et al.
DRUG METABOLISM AND DISPOSITION (2011)
Evaluation of the Effects of Mitragyna speciosa Alkaloid Extract on Cytochrome P450 Enzymes Using a High Throughput Assay
Wai Mun Kong et al.
MOLECULES (2011)
Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation
Chun Yip Chan et al.
TOXICOLOGY LETTERS (2011)
Evaluation of Selected Malaysian Medicinal Plants on Phase I Drug Metabolizing Enzymes, CYP2C9, CYP2D6 and CYP3A4 Activities in vitro
N.A. Hanapi et al.
International Journal of Pharmacology (2010)
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
Scott W. Grimm et al.
DRUG METABOLISM AND DISPOSITION (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry
Anika A. Philipp et al.
JOURNAL OF MASS SPECTROMETRY (2009)
Metabolic activation of a novel 3-substituted indole-containing TNF-α inhibitor:: Dehydrogenation and inactivation of CYP3A4
Hao Sun et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions
Liana Urichuk et al.
CURRENT DRUG METABOLISM (2008)
Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
Magang Shou et al.
DRUG METABOLISM AND DISPOSITION (2008)
Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions
Aleksandra Galetin et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
2,5-Dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6
Andreas H. Ewald et al.
TOXICOLOGY LETTERS (2008)
Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions
R. Scott Obach et al.
DRUG METABOLISM AND DISPOSITION (2007)
Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs
T Niwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
A comprehensive listing of bioactivation pathways of organic functional groups
AS Kalgutkar et al.
CURRENT DRUG METABOLISM (2005)
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes
B Lalovic et al.
DRUG METABOLISM AND DISPOSITION (2004)
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
A LLerena et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Share Paper
